Degrading oncogenic proteins with novel bacterial approaches
What's under the hood with a personalised cancer vaccine? Quite a lot it seems!
Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?
Exploring a novel approach to overcoming immunotherapy resistance
Oncogenes and tumour suppressors can have surprising effects on targeted therapies and immunotherapies
new approaches to applying translational research to the clinic in oncology R&D
An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.
A look at progress and new developments in cancer biomarker developments
Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies
What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?
A new emerging IO target of interest caught out attention, now what?
A novel epigenetic target may have far-reaching outcomes for cancer patients
The ups and downs of CAR-T cell therapy development continues apace
Where are they now four years on? A look at the BET/Bromodomain landscape
Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?
How can we go about improving cell therapy approaches?
Manipulating immune cells in order to harness great antitumour responses to immunotherapy
Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus
An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy
Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
What's new about p53 mutants and MDM2 inhibitors?
Should you read a book on the History of Cancer Immunotherapy? Here's our review...
New insights emerging from research on cytokines as an effective way to induce anti tumour immunity
On targeting immunosuppression and some obscure oncogenic targets
Five key recent papers that are well worth looking at and what the science teaches us about next directions
Rumination, notes and updates on CAR-T cell therapy, checkpoint blockade, SCLC, genomics and TCR signalling...
New series on Key Trends in Oncology for 2018
Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.
After recent readouts of breast cancer trials at #ASCO17, where do we go next for future combos? Based on recent preclinical research, we have some ideas...
The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.
July Journal Club explores some intriguing new data around a cancer immunotherapy theme
A fireside chat with a leading KOL involved in cancer research on resistance.
A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.
A look at what we can learn from some recently published new papers in the oncology space.
Launch of the BSB Journal Club - this inaugural edition explores T cell dysfunction and exhaustion
